US FDA notes 22 observations at Lupin’s Indian base

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Andrey_Kuzmin)
(Image: Getty/Andrey_Kuzmin)

Related tags Lupin Pharmaceuticals Fda cephalosporin

Lupin has received 22 observations across three facilities at its Mandideep campus, which the company says are only ‘procedural in nature’.

The US Food and Drug Administration (FDA) carried out inspections between November 26 and December 4, 2018.

The Mandideep facilities produce active pharmaceutical ingredients (APIs) for its blood pressure drugs, as well as APIs for, and solid oral dosage forms of, cephalosporin – a first line antibiotic.

The company noted, “The inspection at Unit-1, the cephalosporin facilities, closed with 10 observations for the cephalosporin API facilities and eight observations for the cephalosporin Solid Oral Dosage Form facility.

“The inspection at Unit-2, the Cardiovascular ‘Pril’ API facilities, closed with four observations,” ​the statement continued.

While Lupin suggested​ the observations were “largely procedural in nature”​, the FDA did identify gaps in the aseptic processing areas of the cephalosporin API block.

The company is already working to address the issues, with a ‘Quality Management System and Compliance Sustainability Plan’ underway to address some of the issues raised by the FDA.

A spokesperson for Lupin stated that no further details could be revealed about the inspection outcomes.

During an August inspection​ this year, the FDA also detected procedural issues at Lupin’s facility in Tarapur, India. The inspection was prompted by valsartan contamination concerns in the EU and US, an issue that is still causing global recalls​.

However, Lupin’s facilities were found to pose no risk for ‘sartan’ contamination.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more